PRODUCTION AND PERSISTENCE OF SPECIFIC ANTIBODIES IN COVID-19 PATIENTS WITH HEMATOLOGIC MALIGNANCIES: ROLE OF RITUXIMAB

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Abstract The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown.A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), mu

read more